Regenicin Inc
OTC:RGIN
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
R
|
Regenicin Inc
OTC:RGIN
|
153 USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
184.2B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.3B EUR |
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
44.6B USD |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
274.1B CNY |
Loading...
|
|
| DE |
|
BioNTech SE
NASDAQ:BNTX
|
27.5B USD |
Loading...
|
|
| DK |
|
Genmab A/S
CSE:GMAB
|
127.3B DKK |
Loading...
|
|
| US |
|
United Therapeutics Corp
NASDAQ:UTHR
|
20B USD |
Loading...
|
|
| US |
|
Incyte Corp
NASDAQ:INCY
|
19.6B USD |
Loading...
|
|
| US |
|
Revolution Medicines Inc
NASDAQ:RVMD
|
18.7B USD |
Loading...
|
Market Distribution
Other Profitability Ratios
Regenicin Inc
Glance View
Regenicin, Inc. is a biotechnology company, which specializes in the development of regenerative cell therapies to restore the health of damaged tissues and organs. The company is headquartered in Little Falls, New Jersey. The company went IPO on 2008-05-12. The firm is focused on developing and commercializing a lifesaving technology by the introduction of tissue-engineered skin substitutes to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a range of plastic surgery procedures. Its product, NovaDerm, is a multi-layered tissue-engineered skin prepared by utilizing autologous skin cells. NovaDerm is a graftable cultured epithelium skin substitute containing both epidermal and dermal components. The firm is focused on developing its product, TempaDerm. TempaDerm cells develop banks of cryo-preserved (frozen) cells and cultured skin substitute to provide a continuous supply of non-allogenic skin substitutes to treat smaller wound areas on patients, such as ulcers. Its application are used for treatment of chronic skin wounds.